Fertio Aps

Beskrivelse af virksomhedens væsentligste aktiviteter

Primary activitiesFertio ApS’s primary activities are within the fertility industry and related production
.​The company in 2025 changed its primary name to Fertio Aps, retaining its former name: European Sperm Bank as a secondary name. Both names will be used going forward.
​The purpose of the introduction of the name Fertio was to enable future expansion of scope of services beyond sperm banking.

Beskrivelse af usikkerhed ved indregning eller måling

Uncertainty relating to recognition and measurementMeasurement of certain assets and liabilities is based on accounting estimates made by Management. These
estimates are made in accordance with the accounting policies and based on Management’s assumptions and
experience. The estimates made are considered realistic and prudent.
The areas subject to assumptions and estimates that are considered material to the financial statements are
intangible assets, investments in group enterprises, inventories and other provisions.
Specifically inventories are subject to assumptions and estimates as the number of sellable straws depends on many factors such as donor characteristics and regulatory restrictions for provision of donor sperm.
Inventories are measured at cost including direct and indirect production costs. Indirect production costs are assessed on an ongoing basis to ensure relevant and reliable measurement.
Changes in assumptions, estimates and assessment of indirect production costs may have an impact on the
gross margin and the overall valuation of inventory.
Apart from this, there are no particular uncertainties relating to recognition and measurement.

Beskrivelse af usædvanlige forhold, der kan have påvirket indregningen eller målingen

Unusual circumstances affecting recognition and measurementNo significant unusual circumstances affecting recognition and measurement have occurred.

Beskrivelse af udviklingen i virksomhedens aktiviteter og økonomiske forhold

Development in activities and financesManagement considers the result for the financial year to be in line with the expectations for the core business. Operating profit decreased to 28 mDKK in 2024, impacted by a non-recurring inventory provision, and closure of the laboratory facility in London. Excluding these effects, the company maintained a solid operational performance.

Omtale af betydningsfulde hændelser, som er indtruffet efter regnskabsårets afslutning

Events after the balance sheet dateNo events have occurred after the balance sheet date to this date, which would influence the evaluation of this
annual report.

Beskrivelse af virksomhedens forventede udvikling

OutlookFor 2025 Management expects operating profit between 80-90 mDKK and net result between 52-62 mDKK.